Evelo Biosciences, Inc. (Nasdaq:EVLO), Rutgers University, and Robert Wood Johnson University Hospital today announced the submission of an Investigational New Drug (IND) application for an Evelo-sponsored Phase 2 clinical study evaluating the safety and efficacy of EDP1815 for the treatment of hospitalized patients with newly diagnosed COVID-19. The study will be led by Reynold A. Panettieri, Jr., M.D., Vice Chancellor for Translational Medicine and Science at Rutgers Biomedical and Health Sciences and Professor of Medicine at Rutgers Robert Wood Johnson Medical School. To read the full story.
- To Reduce Smoking Rates in Prisons, Cessation Programs Must Be Expanded and Extended.
- Rutgers Selected as Backup Center for New National 9-8-8 Mental Health Crisis Line.
- New NJACTS Publication
- Why do some people evade COVID-19 while others get reinfected?
- Rutgers Scientist Who Researches the Sense of Smell Named Rita Allen Foundation Scholar.